Which has better valuation and earnings, DRUG or IRON?

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bright Minds Biosciences N/A N/A -$8.74M -$2.44 N/A Disc Medicine N/A N/A -$212.18M -$6.62 N/A

Is DRUG or IRON more profitable?

Bright Minds Biosciences' return on equity of -20.58% beat Disc Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Bright Minds Biosciences N/A -20.58% -20.25% Disc Medicine N/A -36.94% -33.88%

Does the media refer more to DRUG or IRON?

In the previous week, Disc Medicine had 1 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 6 mentions for Disc Medicine and 5 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.31 beat Disc Medicine's score of 0.53 indicating that Bright Minds Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bright Minds Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Disc Medicine 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate DRUG or RGC?

Bright Minds Biosciences currently has a consensus price target of $143.83, indicating a potential upside of 101.64%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Bright Minds Biosciences is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, DRUG or RGC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bright Minds Biosciences N/A N/A -$8.74M -$2.44 N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Is DRUG or RGC more profitable?

Regencell Bioscience's return on equity of 0.00% beat Bright Minds Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Bright Minds Biosciences N/A -20.58% -20.25% Regencell Bioscience N/A N/A N/A

Does the media refer more to DRUG or RGC?

In the previous week, Bright Minds Biosciences had 2 more articles in the media than Regencell Bioscience. MarketBeat recorded 5 mentions for Bright Minds Biosciences and 3 mentions for Regencell Bioscience. Bright Minds Biosciences' average media sentiment score of 1.31 beat Regencell Bioscience's score of 0.55 indicating that Bright Minds Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bright Minds Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regencell Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, DRUG or KOD?

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bright Minds Biosciences N/A N/A -$8.74M -$2.44 N/A Kodiak Sciences N/A N/A -$229.97M -$4.17 N/A

Is DRUG or KOD more profitable?

Bright Minds Biosciences' return on equity of -20.58% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Bright Minds Biosciences N/A -20.58% -20.25% Kodiak Sciences N/A -253.85% -81.48%

Which has stronger valuation and earnings, MBX or DRUG?

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MBX Biosciences N/A N/A -$86.97M -$2.21 N/A Bright Minds Biosciences N/A N/A -$8.74M -$2.44 N/A

Is MBX or DRUG more profitable?

Bright Minds Biosciences' return on equity of -20.58% beat MBX Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets MBX Biosciences N/A -24.52% -23.59% Bright Minds Biosciences N/A -20.58% -20.25%

Does the media prefer MBX or DRUG?

In the previous week, MBX Biosciences had 1 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 6 mentions for MBX Biosciences and 5 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.31 beat MBX Biosciences' score of 0.29 indicating that Bright Minds Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Bright Minds Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Bright Minds Biosciences (DRUG) Competitors

$71.33 +0.04 (+0.06%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$71.13 -0.20 (-0.28%)

As of 07/24/2026 07:34 PM Eastern

Compare

DRUG vs. IRON, MOR, RGC, KOD, and MBX

Should you buy Bright Minds Biosciences stock or one of its competitors? MarketBeat compares Bright Minds Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bright Minds Biosciences include Disc Medicine (IRON), MorphoSys (MOR), Regencell Bioscience (RGC), Kodiak Sciences (KOD), and MBX Biosciences (MBX). These companies are all part of the "pharmaceutical products" industry.

How does Bright Minds Biosciences compare to Disc Medicine?

Bright Minds Biosciences (NASDAQ:DRUG) and Disc Medicine (NASDAQ:IRON) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Bright Minds Biosciences presently has a consensus price target of $143.83, indicating a potential upside of 101.64%. Disc Medicine has a consensus price target of $104.44, indicating a potential upside of 40.91%. Given Bright Minds Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Bright Minds Biosciences is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 83.7% of Disc Medicine shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by insiders. Comparatively, 3.8% of Disc Medicine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Bright Minds Biosciences has a beta of -5.34, indicating that its stock price is 634% less volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

In the previous week, Disc Medicine had 1 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 6 mentions for Disc Medicine and 5 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.31 beat Disc Medicine's score of 0.53 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bright Minds Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Disc Medicine	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bright Minds Biosciences' return on equity of -20.58% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
Disc Medicine	N/A	-36.94%	-33.88%

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A

Summary

Bright Minds Biosciences beats Disc Medicine on 9 of the 14 factors compared between the two stocks.

How does Bright Minds Biosciences compare to MorphoSys?

Bright Minds Biosciences (NASDAQ:DRUG) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by company insiders. Comparatively, 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Bright Minds Biosciences has a beta of -5.34, indicating that its share price is 634% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market.

In the previous week, Bright Minds Biosciences had 5 more articles in the media than MorphoSys. MarketBeat recorded 5 mentions for Bright Minds Biosciences and 0 mentions for MorphoSys. Bright Minds Biosciences' average media sentiment score of 1.31 beat MorphoSys' score of 0.00 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Bright Minds Biosciences	Positive
MorphoSys	Neutral

Bright Minds Biosciences has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Bright Minds Biosciences' return on equity of -20.58% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
MorphoSys	-226.79%	-694.31%	-22.55%

Bright Minds Biosciences currently has a consensus target price of $143.83, indicating a potential upside of 101.64%. Given Bright Minds Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Bright Minds Biosciences is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Bright Minds Biosciences has higher earnings, but lower revenue than MorphoSys. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

Summary

Bright Minds Biosciences beats MorphoSys on 13 of the 16 factors compared between the two stocks.

How does Bright Minds Biosciences compare to Regencell Bioscience?

Bright Minds Biosciences (NASDAQ:DRUG) and Regencell Bioscience (NASDAQ:RGC) are both pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Bright Minds Biosciences had 2 more articles in the media than Regencell Bioscience. MarketBeat recorded 5 mentions for Bright Minds Biosciences and 3 mentions for Regencell Bioscience. Bright Minds Biosciences' average media sentiment score of 1.31 beat Regencell Bioscience's score of 0.55 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bright Minds Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regencell Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regencell Bioscience's return on equity of 0.00% beat Bright Minds Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
Regencell Bioscience	N/A	N/A	N/A

Bright Minds Biosciences has a beta of -5.34, indicating that its share price is 634% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.84, indicating that its share price is 84% more volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by company insiders. Comparatively, 2.0% of Regencell Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Bright Minds Biosciences currently has a consensus price target of $143.83, indicating a potential upside of 101.64%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Bright Minds Biosciences is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Bright Minds Biosciences beats Regencell Bioscience on 8 of the 12 factors compared between the two stocks.

How does Bright Minds Biosciences compare to Kodiak Sciences?

Bright Minds Biosciences (NASDAQ:DRUG) and Kodiak Sciences (NASDAQ:KOD) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Bright Minds Biosciences presently has a consensus target price of $143.83, suggesting a potential upside of 101.64%. Kodiak Sciences has a consensus target price of $42.14, suggesting a potential upside of 1.77%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Bright Minds Biosciences is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A

Bright Minds Biosciences has a beta of -5.34, meaning that its share price is 634% less volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.19, meaning that its share price is 119% more volatile than the broader market.

In the previous week, Bright Minds Biosciences had 4 more articles in the media than Kodiak Sciences. MarketBeat recorded 5 mentions for Bright Minds Biosciences and 1 mentions for Kodiak Sciences. Bright Minds Biosciences' average media sentiment score of 1.31 beat Kodiak Sciences' score of 0.94 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Bright Minds Biosciences	Positive
Kodiak Sciences	Positive

40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by company insiders. Comparatively, 44.4% of Kodiak Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Bright Minds Biosciences' return on equity of -20.58% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
Kodiak Sciences	N/A	-253.85%	-81.48%

Summary

Bright Minds Biosciences beats Kodiak Sciences on 9 of the 13 factors compared between the two stocks.

How does Bright Minds Biosciences compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Bright Minds Biosciences (NASDAQ:DRUG) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

MBX Biosciences has a beta of 0.16, meaning that its share price is 84% less volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.34, meaning that its share price is 634% less volatile than the broader market.

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A

40.5% of Bright Minds Biosciences shares are held by institutional investors. 31.1% of MBX Biosciences shares are held by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, MBX Biosciences had 1 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 6 mentions for MBX Biosciences and 5 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.31 beat MBX Biosciences' score of 0.29 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bright Minds Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bright Minds Biosciences' return on equity of -20.58% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-24.52%	-23.59%
Bright Minds Biosciences	N/A	-20.58%	-20.25%

MBX Biosciences currently has a consensus price target of $66.75, suggesting a potential upside of 7.66%. Bright Minds Biosciences has a consensus price target of $143.83, suggesting a potential upside of 101.64%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Bright Minds Biosciences is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Bright Minds Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14

Summary

Bright Minds Biosciences beats MBX Biosciences on 8 of the 13 factors compared between the two stocks.

Get Bright Minds Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DRUG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DRUG vs. The Competition

Export

Metric	Bright Minds Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$693.81M	$3.67B	$6.88B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-29.23	21.11	27.00	23.71
Price / Sales	N/A	165.33	492.77	76.09
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	8.56	7.88	10.28	6.07
Net Income	-$8.74M	$23.81M	$3.60B	$331.84M
7 Day Performance	-6.29%	-3.79%	-1.25%	-1.53%
1 Month Performance	12.08%	-2.59%	-0.35%	-2.46%
1 Year Performance	101.16%	32.85%	18.41%	13.66%

Bright Minds Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DRUG Bright Minds Biosciences	3.132 of 5 stars	$71.33 +0.1%	$143.83 +101.6%	+123.0%	$693.81M	N/A	N/A	N/A	News Coverage Positive News Analyst Upgrade
IRON Disc Medicine	2.0557 of 5 stars	$75.14 -1.1%	$104.44 +39.0%	+22.4%	$2.87B	N/A	N/A	30
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
RGC Regencell Bioscience	0.2822 of 5 stars	$5.66 +12.0%	N/A	-62.3%	$2.80B	N/A	N/A	10
KOD Kodiak Sciences	1.1176 of 5 stars	$43.26 +5.3%	$42.14 -2.6%	+401.9%	$2.71B	N/A	N/A	90	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DRUG) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bright Minds Biosciences (DRUG) Competitors

DRUG vs. IRON, MOR, RGC, KOD, and MBX

How does Bright Minds Biosciences compare to Disc Medicine?

Summary

How does Bright Minds Biosciences compare to MorphoSys?

Summary

How does Bright Minds Biosciences compare to Regencell Bioscience?

Summary

How does Bright Minds Biosciences compare to Kodiak Sciences?

Summary

How does Bright Minds Biosciences compare to MBX Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRUG vs. The Competition

Bright Minds Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bright Minds Biosciences (DRUG) Competitors

DRUG vs. IRON, MOR, RGC, KOD, and MBX

How does Bright Minds Biosciences compare to Disc Medicine?

Do analysts rate DRUG or IRON?

Do insiders and institutionals hold more shares of DRUG or IRON?

Which has more volatility and risk, DRUG or IRON?

Does the media refer more to DRUG or IRON?

Is DRUG or IRON more profitable?

Which has better valuation and earnings, DRUG or IRON?

Summary

How does Bright Minds Biosciences compare to MorphoSys?

Do insiders & institutionals hold more shares of DRUG or MOR?

Which has more volatility & risk, DRUG or MOR?

Does the media refer more to DRUG or MOR?

Is DRUG or MOR more profitable?

Do analysts rate DRUG or MOR?

Which has higher earnings & valuation, DRUG or MOR?

Summary

How does Bright Minds Biosciences compare to Regencell Bioscience?

Does the media refer more to DRUG or RGC?

Is DRUG or RGC more profitable?

Which has more risk and volatility, DRUG or RGC?

Which has preferable earnings and valuation, DRUG or RGC?

Do institutionals and insiders believe in DRUG or RGC?

Do analysts rate DRUG or RGC?

Summary

How does Bright Minds Biosciences compare to Kodiak Sciences?

Do analysts recommend DRUG or KOD?

Which has preferable earnings and valuation, DRUG or KOD?

Which has more risk & volatility, DRUG or KOD?

Does the media favor DRUG or KOD?

Do institutionals & insiders hold more shares of DRUG or KOD?

Is DRUG or KOD more profitable?

Summary

How does Bright Minds Biosciences compare to MBX Biosciences?

Which has more risk & volatility, MBX or DRUG?

Which has stronger valuation and earnings, MBX or DRUG?

Do insiders and institutionals have more ownership in MBX or DRUG?

Does the media prefer MBX or DRUG?

Is MBX or DRUG more profitable?

Do analysts rate MBX or DRUG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRUG vs. The Competition

Bright Minds Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools